Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.28

0.89 (2.75%)

, TEVA

Teva

$32.78

-0.41 (-1.24%)

13:57
07/14/17
07/14
13:57
07/14/17
13:57

AstraZeneca CEO plans on staying at company, Bloomberg reports

AstraZeneca (AZN) CEO Pascal Soriot plans on staying with the company for the foreseeable future, Bloomberg reports, citing people with knowledge of the matter. Israel's Calcalist reported Wednesday night that Soriot agreed to become the CEO of Teva Pharmaceutical (TEVA).

AZN

AstraZeneca

$33.28

0.89 (2.75%)

TEVA

Teva

$32.78

-0.41 (-1.24%)

  • 19

    Jul

  • 03

    Aug

  • 30

    Aug

AZN AstraZeneca
$33.28

0.89 (2.75%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
TEVA Teva
$32.78

-0.41 (-1.24%)

07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
06/27/17
WELS
06/27/17
NO CHANGE
WELS
Market Perform
Teva TV-45070 trial miss a 'modest disappointment,' says Wells Fargo
Wells Fargo analyst David Maris said TV-45070 has not been a focus for Teva (TEVA) investors, but he still views the news that the company and partner Xenon Pharmaceuticals' (XENE) Phase 2 trial in post-herpetic neuralgia missed its primary endpoint as a "modest disappointment" given the need for Teva's pipeline to offset the tough generic market and the eventual competition for Copaxone. Maris keeps a Market Perform rating on Teva.

TODAY'S FREE FLY STORIES

RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

, AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

12:02
11/21/18
11/21
12:02
11/21/18
12:02
Recommendations
Dr. Reddy's, Aquestive Therapeutics analyst commentary  »

BMO says Aquestive loss…

RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AET

Aetna

$205.78

1.635 (0.80%)

, CVS

CVS Health

$75.77

0.25 (0.33%)

12:02
11/21/18
11/21
12:02
11/21/18
12:02
Hot Stocks
NJ state clears CVS-Aetna merger »

According to a filing,…

AET

Aetna

$205.78

1.635 (0.80%)

CVS

CVS Health

$75.77

0.25 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

12:01
11/21/18
11/21
12:01
11/21/18
12:01
General news
EIA natural gas storage change for week ending November 16 »

Gas inventories 134 Bcf…

GS

Goldman Sachs

$193.29

1.95 (1.02%)

11:55
11/21/18
11/21
11:55
11/21/18
11:55
Periodicals
Abu Dhabi fund sues Goldman Sachs over 1MDB scandal, FT says »

Abu Dhabi's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNHBF

ICC International Cannabis

$0.00

(0.00%)

, CGC

Canopy Growth

$34.08

2.17 (6.80%)

11:51
11/21/18
11/21
11:51
11/21/18
11:51
OnTheFly
Rising High: International Cannabis agrees to acquire Green Gene »

Welcome to "Rising High,"…

KNHBF

ICC International Cannabis

$0.00

(0.00%)

CGC

Canopy Growth

$34.08

2.17 (6.80%)

MMNFF

MedMen

$0.00

(0.00%)

ACB

Aurora Cannabis

$6.27

0.23 (3.81%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$8.57

0.38 (4.64%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$0.00

(0.00%)

TLRY

Tilray

$107.50

3.56 (3.43%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

CRM

Salesforce

$124.33

3.61 (2.99%)

11:50
11/21/18
11/21
11:50
11/21/18
11:50
Options
Put spread in Salesforce as shares bounce 3% »

Put spread in Salesforce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Treasury's $11 B 10-year TIPS reopening was ok »

Treasury's $11 B…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Atlanta Fed's Q4 GDPNow estimate was unchanged at 2.5% »

Atlanta Fed's Q4…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Breaking General news story  »

Week of 11/16 EIA Natural…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

, RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

11:44
11/21/18
11/21
11:44
11/21/18
11:44
Recommendations
Aquestive Therapeutics, Dr. Reddy's analyst commentary  »

Aquestive selloff on…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HIG

Hartford Financial

$44.70

0.6 (1.36%)

11:40
11/21/18
11/21
11:40
11/21/18
11:40
Options
Higher option volume in Hartford fueled by call buying »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

11:36
11/21/18
11/21
11:36
11/21/18
11:36
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

11:36
11/21/18
11/21
11:36
11/21/18
11:36
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

11:35
11/21/18
11/21
11:35
11/21/18
11:35
General news
Treasury announced a $111 B package of short dated coupons auctions for next week »

Treasury announced a $111…

BECN

Beacon Roofing

$32.97

4.9 (17.46%)

11:32
11/21/18
11/21
11:32
11/21/18
11:32
Upgrade
Beacon Roofing rating change  »

Beacon Roofing upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PCG

PG&E

$24.20

0.64 (2.72%)

11:30
11/21/18
11/21
11:30
11/21/18
11:30
Options
2K PG&E Mar 28 - 33 call spreads bought for $1.58 »

2K PG&E Mar 28 - 33…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
11/21/18
11/21
11:25
11/21/18
11:25
General news
Treasury's 10-year TIPS preview: the $11 B reopening may be weakened »

Treasury's 10-year…

AMD

AMD

$19.24

0.04 (0.21%)

11:20
11/21/18
11/21
11:20
11/21/18
11:20
Options
Sweep buyers of AMD weekly puts »

Sweep buyers of AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 06

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/21/18
11/21
11:17
11/21/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/21/18
11/21
11:16
11/21/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYAD

Celyad

$26.97

(0.00%)

, BLUE

Bluebird Bio

$116.82

0.55 (0.47%)

11:11
11/21/18
11/21
11:11
11/21/18
11:11
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

CYAD

Celyad

$26.97

(0.00%)

BLUE

Bluebird Bio

$116.82

0.55 (0.47%)

NVS

Novartis

$88.49

1.51 (1.74%)

GILD

Gilead

$67.04

-0.54 (-0.80%)

CELG

Celgene

$67.69

0.93 (1.39%)

AUTL

Autolus Therapeutics

$42.60

1.4 (3.40%)

ALLO

Allogene Therapeutics

$26.40

0.79 (3.08%)

CLLS

Cellectis

$20.89

0.65 (3.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 27

    Nov

  • 27

    Nov

  • 29

    Nov

  • 01

    Dec

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 10

    Dec

  • 13

    Dec

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr FRN Note Announcement CUSIP Number data reported »

2-Yr FRN Note…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr FRN Note Announcement Offering Amount data reported »

2-Yr FRN Note…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.